Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and Hansen Disease

moxifloxacin has been researched along with Hansen Disease in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's2 (28.57)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Adams, LB; Collins, JH; Hagge, DA; Lahiri, R; Lenz, SM; Ray, NA1
Astari, L; Cambau, E; do Nascimento, DC; Gillini, L; Grosset, J; Izumi, S; Kar, HK; Mieras, LF; Prakoeswa, CRS; Saunderson, PR; Scollard, DM; Smith, WCS; Sturkenboom, MGG; Taal, AT; van Brakel, WH; Virmond, MCL1
Aubry, A; Chauffour, A; Escolano, S; Henquet, S; Jarlier, V; Matsuoka, M; Veziris, N1
Abalos, RM; Andaya, CE; Burgos, J; Dela Cruz, E; Fajardo, TT; Gelber, RH; Pardillo, FE; Paredes, RM1
Andries, K; Chauffour, A; Jarlier, V; Ji, B1
Bentoucha, A; Bonnafous, P; Consigny, S; Grosset, J; Ji, B1
Grosset, J; Ji, B1

Trials

1 trial(s) available for moxifloxacin and Hansen Disease

ArticleYear
Powerful bactericidal activity of moxifloxacin in human leprosy.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:9

    Topics: Adult; Animals; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Foot; Humans; Leprosy; Male; Mice; Middle Aged; Moxifloxacin; Mycobacterium leprae; Quinolines; Skin; Treatment Outcome

2008

Other Studies

6 other study(ies) available for moxifloxacin and Hansen Disease

ArticleYear
Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.
    PLoS neglected tropical diseases, 2020, Volume: 14, Issue:9

    Topics: Animals; Asymptomatic Infections; Bacterial Load; Clarithromycin; Drug Combinations; Leprostatic Agents; Leprosy; Mice; Mice, Nude; Minocycline; Moxifloxacin; Mycobacterium leprae; Post-Exposure Prophylaxis; Rifampin

2020
An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+.
    BMC infectious diseases, 2018, Oct-05, Volume: 18, Issue:1

    Topics: Anti-Bacterial Agents; Clarithromycin; Fluoroquinolones; Humans; Leprosy; Moxifloxacin; Netherlands; Post-Exposure Prophylaxis; Rifampin

2018
Resistance of M. leprae to quinolones: a question of relativity?
    PLoS neglected tropical diseases, 2013, Volume: 7, Issue:11

    Topics: Animals; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Leprosy; Mice; Moxifloxacin; Mycobacterium leprae; Quinolines; Quinolones

2013
Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:4

    Topics: Acetamides; Animals; Anti-Infective Agents; Aza Compounds; Diarylquinolines; Female; Fluoroquinolones; Leprosy; Linezolid; Mice; Moxifloxacin; Mycobacterium leprae; Nitroimidazoles; Oxazolidinones; Quinolines

2006
Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.
    Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:10

    Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Foot; Ketolides; Leprostatic Agents; Leprosy; Macrolides; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium leprae; Quinolines; Rifampin; Skin

2000
Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy.
    Leprosy review, 2000, Volume: 71 Suppl

    Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Leprostatic Agents; Leprosy; Mice; Mice, Inbred Strains; Minocycline; Moxifloxacin; Probability; Quinolines; Rifampin; Treatment Outcome

2000